

Bette T Korber

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3365951/publications.pdf>

Version: 2024-02-01

270
papers

41,366
citations

1994

101
h-index

2828

191
g-index

297
all docs

297
docs citations

297
times ranked

28179
citing authors

#	ARTICLE	IF	CITATIONS
1	Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus. <i>Cell</i> , 2020, 182, 812-827.e19.	28.9	3,551
2	Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 7552-7557.	7.1	1,708
3	Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. <i>Nature</i> , 2013, 496, 469-476.	27.8	961
4	Timing the Ancestor of the HIV-1 Pandemic Strains. <i>Science</i> , 2000, 288, 1789-1796.	12.6	819
5	Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA. <i>Nature</i> , 2004, 432, 769-775.	27.8	784
6	Quantifying Residual HIV-1 Replication in Patients Receiving Combination Antiretroviral Therapy. <i>New England Journal of Medicine</i> , 1999, 340, 1605-1613.	27.0	782
7	A new classification for HIV-1. <i>Nature</i> , 1998, 391, 240-240.	27.8	733
8	Diversity Considerations in HIV-1 Vaccine Selection. <i>Science</i> , 2002, 296, 2354-2360.	12.6	731
9	Structure of a V3-Containing HIV-1 gp120 Core. <i>Science</i> , 2005, 310, 1025-1028.	12.6	696
10	Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. <i>Journal of Experimental Medicine</i> , 2009, 206, 1273-1289.	8.5	684
11	Comprehensive Cross-Clade Neutralization Analysis of a Panel of Anti-Human Immunodeficiency Virus Type 1 Monoclonal Antibodies. <i>Journal of Virology</i> , 2004, 78, 13232-13252.	3.4	665
12	Tiered Categorization of a Diverse Panel of HIV-1 Env Pseudoviruses for Assessment of Neutralizing Antibodies. <i>Journal of Virology</i> , 2010, 84, 1439-1452.	3.4	589
13	Envelope-Constrained Neutralization-Sensitive HIV-1 After Heterosexual Transmission. <i>Science</i> , 2004, 303, 2019-2022.	12.6	572
14	The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. <i>Journal of Experimental Medicine</i> , 2009, 206, 1253-1272.	8.5	562
15	Deciphering Human Immunodeficiency Virus Type 1 Transmission and Early Envelope Diversification by Single-Genome Amplification and Sequencing. <i>Journal of Virology</i> , 2008, 82, 3952-3970.	3.4	540
16	Evolution and transmission of stable CTL escape mutations in HIV infection. <i>Nature</i> , 2001, 412, 334-338.	27.8	523
17	An African HIV-1 sequence from 1959 and implications for the origin of the epidemic. <i>Nature</i> , 1998, 391, 594-597.	27.8	479
18	Evolutionary and immunological implications of contemporary HIV-1 variation. <i>British Medical Bulletin</i> , 2001, 58, 19-42.	6.9	423

#	ARTICLE	IF	CITATIONS
19	Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin. <i>Glycobiology</i> , 2004, 14, 1229-1246.	2.5	409
20	Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. <i>Nature Medicine</i> , 2007, 13, 100-106.	30.7	400
21	Phenotypic properties of transmitted founder HIV-1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 6626-6633.	7.1	379
22	Trimeric HIV-1-Env Structures Define Glycan Shields from Clades A, B, and G. <i>Cell</i> , 2016, 165, 813-826.	28.9	379
23	Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses. <i>Journal of Experimental Medicine</i> , 2018, 215, 1571-1588.	8.5	366
24	Quantitating the Multiplicity of Infection with Human Immunodeficiency Virus Type 1 Subtype C Reveals a Non-Poisson Distribution of Transmitted Variants. <i>Journal of Virology</i> , 2009, 83, 3556-3567.	3.4	354
25	Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. <i>Nature Medicine</i> , 2010, 16, 319-323.	30.7	351
26	SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination. <i>New England Journal of Medicine</i> , 2022, 386, 1088-1091.	27.0	338
27	Genetic and Neutralization Properties of Subtype C Human Immunodeficiency Virus Type 1 Molecular env Clones from Acute and Early Heterosexually Acquired Infections in Southern Africa. <i>Journal of Virology</i> , 2006, 80, 11776-11790.	3.4	334
28	Protective Efficacy of a Global HIV-1 Mosaic Vaccine against Heterologous SHIV Challenges in Rhesus Monkeys. <i>Cell</i> , 2013, 155, 531-539.	28.9	334
29	Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection. <i>Aids</i> , 2014, 28, 163-169.	2.2	334
30	SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines. <i>Cell Host and Microbe</i> , 2021, 29, 529-539.e3.	11.0	324
31	HIV-1 superinfection despite broad CD8+ T-cell responses containing replication of the primary virus. <i>Nature</i> , 2002, 420, 434-439.	27.8	321
32	Effect of natural mutations of SARS-CoV-2 on spike structure, conformation, and antigenicity. <i>Science</i> , 2021, 373, .	12.6	318
33	Advantage of rare HLA supertype in HIV disease progression. <i>Nature Medicine</i> , 2003, 9, 928-935.	30.7	311
34	D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization. <i>Cell Host and Microbe</i> , 2021, 29, 23-31.e4.	11.0	308
35	Emergence of SARS-CoV-2 through recombination and strong purifying selection. <i>Science Advances</i> , 2020, 6, .	10.3	307
36	Maturation Pathway from Germline to Broad HIV-1 Neutralizer of a CD4-Mimic Antibody. <i>Cell</i> , 2016, 165, 449-463.	28.9	305

#	ARTICLE	IF	CITATIONS
37	Breadth of Human Immunodeficiency Virus-Specific Neutralizing Activity in Sera: Clustering Analysis and Association with Clinical Variables. <i>Journal of Virology</i> , 2010, 84, 1631-1636.	3.4	304
38	Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1. <i>Journal of Experimental Medicine</i> , 2009, 206, 1117-1134.	8.5	295
39	Relative Dominance of Gag p24-Specific Cytotoxic T Lymphocytes Is Associated with Human Immunodeficiency Virus Control. <i>Journal of Virology</i> , 2006, 80, 3122-3125.	3.4	275
40	Global Panel of HIV-1 Env Reference Strains for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies. <i>Journal of Virology</i> , 2014, 88, 2489-2507.	3.4	274
41	Consistent Cytotoxic-T-Lymphocyte Targeting of Immunodominant Regions in Human Immunodeficiency Virus across Multiple Ethnicities. <i>Journal of Virology</i> , 2004, 78, 2187-2200.	3.4	270
42	Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19). <i>Lancet, The</i> , 2018, 392, 232-243.	13.7	269
43	Cooperation of B Cell Lineages in Induction of HIV-1-Broadly Neutralizing Antibodies. <i>Cell</i> , 2014, 158, 481-491.	28.9	266
44	High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men. <i>PLoS Pathogens</i> , 2010, 6, e1000890.	4.7	263
45	Broadly targeted CD8 ⁺ T cell responses restricted by major histocompatibility complex E. <i>Science</i> , 2016, 351, 714-720.	12.6	260
46	Transmission of Single HIV-1 Genomes and Dynamics of Early Immune Escape Revealed by Ultra-Deep Sequencing. <i>PLoS ONE</i> , 2010, 5, e12303.	2.5	259
47	Signature Pattern Analysis: A Method for Assessing Viral Sequence Relatedness. <i>AIDS Research and Human Retroviruses</i> , 1992, 8, 1549-1560.	1.1	253
48	Design and Pre-Clinical Evaluation of a Universal HIV-1 Vaccine. <i>PLoS ONE</i> , 2007, 2, e984.	2.5	247
49	Clustering Patterns of Cytotoxic T-Lymphocyte Epitopes in Human Immunodeficiency Virus Type 1 (HIV-1) Proteins Reveal Imprints of Immune Evasion on HIV-1 Global Variation. <i>Journal of Virology</i> , 2002, 76, 8757-8768.	3.4	241
50	Selection for Human Immunodeficiency Virus Type 1 Envelope Glycosylation Variants with Shorter V1-V2 Loop Sequences Occurs during Transmission of Certain Genetic Subtypes and May Impact Viral RNA Levels. <i>Journal of Virology</i> , 2005, 79, 6528-6531.	3.4	241
51	The Emergence of Simian/Human Immunodeficiency Viruses. <i>AIDS Research and Human Retroviruses</i> , 1992, 8, 373-386.	1.1	238
52	Founder Effects in the Assessment of HIV Polymorphisms and HLA Allele Associations. <i>Science</i> , 2007, 315, 1583-1586.	12.6	234
53	SARS-CoV-2 Variants of Interest and Concern naming scheme conducive for global discourse. <i>Nature Microbiology</i> , 2021, 6, 821-823.	13.3	221
54	Transmission and accumulation of CTL escape variants drive negative associations between HIV polymorphisms and HLA. <i>Journal of Experimental Medicine</i> , 2005, 201, 891-902.	8.5	220

#	ARTICLE	IF	CITATIONS
55	Plasma IgG to Linear Epitopes in the V2 and V3 Regions of HIV-1 gp120 Correlate with a Reduced Risk of Infection in the RV144 Vaccine Efficacy Trial. <i>PLoS ONE</i> , 2013, 8, e75665.	2.5	214
56	Staged induction of HIV-1 glycanâ€‘dependent broadly neutralizing antibodies. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	212
57	Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys. <i>Nature Medicine</i> , 2010, 16, 324-328.	30.7	211
58	Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes. <i>Nature Immunology</i> , 2006, 7, 173-178.	14.5	209
59	Quantitative Deep Sequencing Reveals Dynamic HIV-1 Escape and Large Population Shifts during CCR5 Antagonist Therapy In Vivo. <i>PLoS ONE</i> , 2009, 4, e5683.	2.5	205
60	Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351. <i>New England Journal of Medicine</i> , 2021, 384, 2352-2354.	27.0	202
61	Maternal HIV-1 viral load and vertical transmission of infection: The Ariel Project for the prevention of HIV transmission from mother to infant. <i>Nature Medicine</i> , 1997, 3, 549-552.	30.7	200
62	Genetic and Phenotypic Analyses of Human Immunodeficiency Virus Type 1 Escape from a Small-Molecule CCR5 Inhibitor. <i>Journal of Virology</i> , 2004, 78, 2790-2807.	3.4	195
63	The Thai Phase III HIV Type 1 Vaccine Trial (RV144) Regimen Induces Antibodies That Target Conserved Regions Within the V2 Loop of gp120. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 1444-1457.	1.1	191
64	Antigenicity and Immunogenicity of a Synthetic Human Immunodeficiency Virus Type 1 Group M Consensus Envelope Glycoprotein. <i>Journal of Virology</i> , 2005, 79, 1154-1163.	3.4	189
65	A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses. <i>Virology</i> , 2006, 353, 268-282.	2.4	176
66	Systematic Analysis of Monoclonal Antibodies against Ebola Virus GP Defines Features that Contribute to Protection. <i>Cell</i> , 2018, 174, 938-952.e13.	28.9	173
67	Analysis of V2 Antibody Responses Induced in Vaccinees in the ALVAC/AIDS VAX HIV-1 Vaccine Efficacy Trial. <i>PLoS ONE</i> , 2013, 8, e53629.	2.5	165
68	Vertical T cell immunodominance and epitope entropy determine HIV-1 escape. <i>Journal of Clinical Investigation</i> , 2013, 123, 380-93.	8.2	165
69	Modeling sequence evolution in acute HIV-1 infection. <i>Journal of Theoretical Biology</i> , 2009, 261, 341-360.	1.7	162
70	HIV Evolution in Early Infection: Selection Pressures, Patterns of Insertion and Deletion, and the Impact of APOBEC. <i>PLoS Pathogens</i> , 2009, 5, e1000414.	4.7	161
71	Early Low-Titer Neutralizing Antibodies Impede HIV-1 Replication and Select for Virus Escape. <i>PLoS Pathogens</i> , 2012, 8, e1002721.	4.7	159
72	Immunoinformatics Comes of Age. <i>PLoS Computational Biology</i> , 2006, 2, e71.	3.2	156

#	ARTICLE	IF	CITATIONS
73	The SARS-CoV-2 Spike variant D614G favors an open conformational state. <i>Science Advances</i> , 2021, 7, .	10.3	156
74	Immune control of HIV: the obstacles of HLA and viral diversity. <i>Nature Immunology</i> , 2001, 2, 473-475.	14.5	153
75	Evidence of Differential HLA Class I-Mediated Viral Evolution in Functional and Accessory/Regulatory Genes of HIV-1. <i>PLoS Pathogens</i> , 2007, 3, e94.	4.7	153
76	Diversity of V3 Region Sequences of Human Immunodeficiency Viruses Type 1 from the Central African Republic. <i>AIDS Research and Human Retroviruses</i> , 1993, 9, 997-1006.	1.1	150
77	HIV-1 Evolution and Disease Progression. <i>Science</i> , 1996, 274, 1008-1011.	12.6	150
78	Impact of HLA-B Alleles, Epitope Binding Affinity, Functional Avidity, and Viral Coinfection on the Immunodominance of Virus-Specific CTL Responses. <i>Journal of Immunology</i> , 2006, 176, 4094-4101.	0.8	150
79	Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection. <i>PLoS Pathogens</i> , 2016, 12, e1005520.	4.7	150
80	Genetic and Functional Analysis of Full-Length Human Immunodeficiency Virus Type 1 env Genes Derived from Brain and Blood of Patients with AIDS. <i>Journal of Virology</i> , 2003, 77, 12336-12345.	3.4	149
81	jpHMM: Improving the reliability of recombination prediction in HIV-1. <i>Nucleic Acids Research</i> , 2009, 37, W647-W651.	14.5	145
82	Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques. <i>PLoS Pathogens</i> , 2015, 11, e1005042.	4.7	145
83	Definition of the viral targets of protective HIV-1-specific T cell responses. <i>Journal of Translational Medicine</i> , 2011, 9, 208.	4.4	143
84	HIV-Host Interactions: Implications for Vaccine Design. <i>Cell Host and Microbe</i> , 2016, 19, 292-303.	11.0	143
85	Fitness Costs and Diversity of the Cytotoxic T Lymphocyte (CTL) Response Determine the Rate of CTL Escape during Acute and Chronic Phases of HIV Infection. <i>Journal of Virology</i> , 2011, 85, 10518-10528.	3.4	141
86	Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV. <i>Nature</i> , 2014, 505, 502-508.	27.8	140
87	Quantifying the Diversification of Hepatitis C Virus (HCV) during Primary Infection: Estimates of the In Vivo Mutation Rate. <i>PLoS Pathogens</i> , 2012, 8, e1002881.	4.7	139
88	T-Cell Vaccine Strategies for Human Immunodeficiency Virus, the Virus with a Thousand Faces. <i>Journal of Virology</i> , 2009, 83, 8300-8314.	3.4	137
89	Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge. <i>Nature Communications</i> , 2017, 8, 15711.	12.8	137
90	Enhanced Detection of Human Immunodeficiency Virus Type 1-Specific T-Cell Responses to Highly Variable Regions by Using Peptides Based on Autologous Virus Sequences. <i>Journal of Virology</i> , 2003, 77, 7330-7340.	3.4	133

#	ARTICLE	IF	CITATIONS
91	HLA Class I-Driven Evolution of Human Immunodeficiency Virus Type 1 Subtype C Proteome: Immune Escape and Viral Load. <i>Journal of Virology</i> , 2008, 82, 6434-6446.	3.4	126
92	Structural diversity of the SARS-CoV-2 Omicron spike. <i>Molecular Cell</i> , 2022, 82, 2050-2068.e6.	9.7	125
93	HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design. <i>Cell Host and Microbe</i> , 2019, 25, 59-72.e8.	11.0	124
94	HIV sequence databases. <i>AIDS Reviews</i> , 2003, 5, 52-61.	1.0	124
95	PUBLIC HEALTH: Enhanced: A Sound Rationale Needed for Phase III HIV-1 Vaccine Trials. <i>Science</i> , 2004, 303, 316-316.	12.6	123
96	Improving Neutralization Potency and Breadth by Combining Broadly Reactive HIV-1 Antibodies Targeting Major Neutralization Epitopes. <i>Journal of Virology</i> , 2015, 89, 2659-2671.	3.4	123
97	A Polymorphism in the Regulatory Region of the CC-Chemokine Receptor 5 Gene Influences Perinatal Transmission of Human Immunodeficiency Virus Type 1 to African-American Infants. <i>Journal of Virology</i> , 1999, 73, 10264-10271.	3.4	123
98	Extensive HLA class I allele promiscuity among viral CTL epitopes. <i>European Journal of Immunology</i> , 2007, 37, 2419-2433.	2.9	120
99	Comparison of Viral Env Proteins from Acute and Chronic Infections with Subtype C Human Immunodeficiency Virus Type 1 Identifies Differences in Glycosylation and CCR5 Utilization and Suggests a New Strategy for Immunogen Design. <i>Journal of Virology</i> , 2013, 87, 7218-7233.	3.4	119
100	Potent and broad HIV-neutralizing antibodies in memory B cells and plasma. <i>Science Immunology</i> , 2017, 2, .	11.9	119
101	CATNAP: a tool to compile, analyze and tally neutralizing antibody panels. <i>Nucleic Acids Research</i> , 2015, 43, W213-W219.	14.5	118
102	Defining the risk of SARS-CoV-2 variants on immune protection. <i>Nature</i> , 2022, 605, 640-652.	27.8	117
103	Recurrent Signature Patterns in HIV-1 B Clade Envelope Glycoproteins Associated with either Early or Chronic Infections. <i>PLoS Pathogens</i> , 2011, 7, e1002209.	4.7	114
104	The role of recombination in the emergence of a complex and dynamic HIV epidemic. <i>Retrovirology</i> , 2010, 7, 25.	2.0	110
105	Novel Conserved-region T-cell Mosaic Vaccine With High Global HIV-1 Coverage Is Recognized by Protective Responses in Untreated Infection. <i>Molecular Therapy</i> , 2016, 24, 832-842.	8.2	107
106	Role of donor genital tract HIV-1 diversity in the transmission bottleneck. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, E1156-63.	7.1	106
107	Protection against a mixed SHIV challenge by a broadly neutralizing antibody cocktail. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	106
108	A comprehensive system for consistent numbering of HCV sequences, proteins and epitopes. <i>Hepatology</i> , 2006, 44, 1355-1361.	7.3	105

#	ARTICLE	IF	CITATIONS
109	HIV-1 Nef is preferentially recognized by CD8 T cells in primary HIV-1 infection despite a relatively high degree of genetic diversity. <i>Aids</i> , 2004, 18, 1383-1392.	2.2	99
110	Characterization of Novel Simian Immunodeficiency Viruses from Red-Capped Mangabeys from Nigeria (SIVrcmNG409 and -NG411). <i>Journal of Virology</i> , 2001, 75, 12014-12027.	3.4	96
111	Unique Mutational Patterns in the Envelope ± 2 Amphipathic Helix and Acquisition of Length in gp120 Hypervariable Domains Are Associated with Resistance to Autologous Neutralization of Subtype C Human Immunodeficiency Virus Type 1. <i>Journal of Virology</i> , 2007, 81, 5658-5668.	3.4	92
112	Completeness of HIV-1 Envelope Glycan Shield at Transmission Determines Neutralization Breadth. <i>Cell Reports</i> , 2018, 25, 893-908.e7.	6.4	91
113	Human leukocyte antigen-associated sequence polymorphisms in hepatitis C virus reveal reproducible immune responses and constraints on viral evolution. <i>Hepatology</i> , 2007, 46, 339-349.	7.3	90
114	Relationship between Functional Profile of HIV-1 Specific CD8 T Cells and Epitope Variability with the Selection of Escape Mutants in Acute HIV-1 Infection. <i>PLoS Pathogens</i> , 2011, 7, e1001273.	4.7	90
115	HIV-1 Vaccine Development After STEP. <i>Annual Review of Medicine</i> , 2010, 61, 153-167.	12.2	89
116	Large-scale amplification, cloning and sequencing of near full-length HIV-1 subtype C genomes. <i>Journal of Virological Methods</i> , 2006, 136, 118-125.	2.1	88
117	Role of Maternal Autologous Neutralizing Antibody in Selective Perinatal Transmission of Human Immunodeficiency Virus Type 1 Escape Variants. <i>Journal of Virology</i> , 2006, 80, 6525-6533.	3.4	87
118	Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	87
119	A jumping profile Hidden Markov Model and applications to recombination sites in HIV and HCV genomes. <i>BMC Bioinformatics</i> , 2006, 7, 265.	2.6	85
120	Fitness costs of rifampicin resistance in <i>Mycobacterium tuberculosis</i> are amplified under conditions of nutrient starvation and compensated by mutation in the β subunit of RNA polymerase. <i>Molecular Microbiology</i> , 2014, 91, 1106-1119.	2.5	85
121	Estimating time since infection in early homogeneous HIV-1 samples using a poisson model. <i>BMC Bioinformatics</i> , 2010, 11, 532.	2.6	83
122	Antigenicity and Immunogenicity of Transmitted/Founder, Consensus, and Chronic Envelope Glycoproteins of Human Immunodeficiency Virus Type 1. <i>Journal of Virology</i> , 2013, 87, 4185-4201.	3.4	83
123	Tracking HIV-1 recombination to resolve its contribution to HIV-1 evolution in natural infection. <i>Nature Communications</i> , 2018, 9, 1928.	12.8	83
124	Using human immunodeficiency virus type 1 sequences to infer historical features of the acquired immune deficiency syndrome epidemic and human immunodeficiency virus evolution. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2001, 356, 855-866.	4.0	82
125	Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization. <i>PLoS Pathogens</i> , 2016, 12, e1005742.	4.7	81
126	Highly complex neutralization determinants on a monophyletic lineage of newly transmitted subtype C HIV-1 Env clones from India. <i>Virology</i> , 2009, 385, 505-520.	2.4	78

#	ARTICLE	IF	CITATIONS
127	Genetic Signatures in the Envelope Glycoproteins of HIV-1 that Associate with Broadly Neutralizing Antibodies. <i>PLoS Computational Biology</i> , 2010, 6, e1000955.	3.2	78
128	Limitations of a Molecular Clock Applied to Considerations of the Origin of HIV-1. <i>Science</i> , 1998, 280, 1868-1871.	12.6	77
129	Proteome-wide analysis of HIV-specific naive and memory CD4+ T cells in unexposed blood donors. <i>Journal of Experimental Medicine</i> , 2014, 211, 1273-1280.	8.5	76
130	A centralized gene-based HIV-1 vaccine elicits broad cross-clade cellular immune responses in rhesus monkeys. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 10489-10494.	7.1	75
131	<i>Mycobacterium tuberculosis</i> "Heterogeneity revealed through whole genome sequencing. <i>Tuberculosis</i> , 2012, 92, 194-201.	1.9	75
132	Impact of Clade, Geography, and Age of the Epidemic on HIV-1 Neutralization by Antibodies. <i>Journal of Virology</i> , 2014, 88, 12623-12643.	3.4	75
133	Elucidation of Hepatitis C Virus Transmission and Early Diversification by Single Genome Sequencing. <i>PLoS Pathogens</i> , 2012, 8, e1002880.	4.7	74
134	Vaccines and Broadly Neutralizing Antibodies for HIV-1 Prevention. <i>Annual Review of Immunology</i> , 2020, 38, 673-703.	21.8	74
135	HIV-1 and SARS-CoV-2: Patterns in the evolution of two pandemic pathogens. <i>Cell Host and Microbe</i> , 2021, 29, 1093-1110.	11.0	73
136	The prolonged culture of human immunodeficiency virus type 1 in primary lymphocytes increases its sensitivity to neutralization by soluble CD4. <i>Virology</i> , 2004, 321, 8-22.	2.4	72
137	Association between Maternal and Infant Class I and II HLA Alleles and of Their Concordance with the Risk of Perinatal HIV Type 1 Transmission. <i>AIDS Research and Human Retroviruses</i> , 2002, 18, 741-746.	1.1	70
138	Vaccine Elicitation of High Mannose-Dependent Neutralizing Antibodies against the V3-Glycan Broadly Neutralizing Epitope in Nonhuman Primates. <i>Cell Reports</i> , 2017, 18, 2175-2188.	6.4	69
139	Genetic Evaluation of Suspected Cases of Transient HIV-1 Infection of Infants. <i>Science</i> , 1998, 280, 1073-1077.	12.6	68
140	Epitope Escape Mutation and Decay of Human Immunodeficiency Virus Type 1-Specific CTL Responses. <i>Journal of Immunology</i> , 2003, 171, 5372-5379.	0.8	68
141	HLA-B63 Presents HLA-B57/B58-Restricted Cytotoxic T-Lymphocyte Epitopes and Is Associated with Low Human Immunodeficiency Virus Load. <i>Journal of Virology</i> , 2005, 79, 10218-10225.	3.4	68
142	Potential of conventional & bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C & D infections. <i>PLoS Pathogens</i> , 2018, 14, e1006860.	4.7	68
143	Clade-Specific Differences between Human Immunodeficiency Virus Type 1 Clades B and C: Diversity and Correlations in C3-V4 Regions of gp120. <i>Journal of Virology</i> , 2007, 81, 4886-4891.	3.4	66
144	Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant Viruses. <i>Cell Host and Microbe</i> , 2015, 18, 354-362.	11.0	66

#	ARTICLE	IF	CITATIONS
145	Los Alamos Hepatitis C Immunology Database. <i>Applied Bioinformatics</i> , 2005, 4, 217-225.	1.6	63
146	Rare HIV-1 transmitted/founder lineages identified by deep viral sequencing contribute to rapid shifts in dominant quasispecies during acute and early infection. <i>PLoS Pathogens</i> , 2017, 13, e1006510.	4.7	63
147	Cross-Subtype T-Cell Immune Responses Induced by a Human Immunodeficiency Virus Type 1 Group M Consensus Env Immunogen. <i>Journal of Virology</i> , 2006, 80, 6745-6756.	3.4	62
148	Extensive Intrasubtype Recombination in South African Human Immunodeficiency Virus Type 1 Subtype C Infections. <i>Journal of Virology</i> , 2007, 81, 4492-4500.	3.4	62
149	Frequent Detection of Escape from Cytotoxic T-Lymphocyte Recognition in Perinatal Human Immunodeficiency Virus (HIV) Type 1 Transmission: the Ariel Project for the Prevention of Transmission of HIV from Mother to Infant. <i>Journal of Virology</i> , 1999, 73, 3975-3985.	3.4	62
150	Expanded Breadth of the T-Cell Response to Mosaic Human Immunodeficiency Virus Type 1 Envelope DNA Vaccination. <i>Journal of Virology</i> , 2009, 83, 2201-2215.	3.4	61
151	Mapping HIV-1 Vaccine Induced T-Cell Responses: Bias towards Less-Conserved Regions and Potential Impact on Vaccine Efficacy in the Step Study. <i>PLoS ONE</i> , 2011, 6, e20479.	2.5	61
152	Host genetic profiles predict virological and immunological control of HIV-1 infection in adolescents. <i>Aids</i> , 2002, 16, 2275-2284.	2.2	58
153	Targeting of a CD8 T Cell Env Epitope Presented by HLA-B*5802 Is Associated with Markers of HIV Disease Progression and Lack of Selection Pressure. <i>AIDS Research and Human Retroviruses</i> , 2008, 24, 72-82.	1.1	58
154	Defining the HLA class I-associated viral antigen repertoire from HIV-1-infected human cells. <i>European Journal of Immunology</i> , 2016, 46, 60-69.	2.9	57
155	Neutralization-guided design of HIV-1 envelope trimers with high affinity for the unmutated common ancestor of CH235 lineage CD4bs broadly neutralizing antibodies. <i>PLoS Pathogens</i> , 2019, 15, e1008026.	4.7	56
156	Consistent Patterns of Change during the Divergence of Human Immunodeficiency Virus Type 1 Envelope from That of the Inoculated Virus in Simian/Human Immunodeficiency Virus-Infected Macaques. <i>Journal of Virology</i> , 2006, 80, 999-1014.	3.4	55
157	Centralized immunogens as a vaccine strategy to overcome HIV-1 diversity. <i>Expert Review of Vaccines</i> , 2004, 3, S161-S168.	4.4	54
158	A Signature in HIV-1 Envelope Leader Peptide Associated with Transition from Acute to Chronic Infection Impacts Envelope Processing and Infectivity. <i>PLoS ONE</i> , 2011, 6, e23673.	2.5	54
159	A Mechanistic Understanding of Allosteric Immune Escape Pathways in the HIV-1 Envelope Glycoprotein. <i>PLoS Computational Biology</i> , 2013, 9, e1003046.	3.2	53
160	Characterization and Comparison of Recombinant Simian Immunodeficiency Virus from Drill () Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 147 4867-4880.	3.4	51
161	The implications of patterns in HIV diversity for neutralizing antibody induction and susceptibility. <i>Current Opinion in HIV and AIDS</i> , 2009, 4, 408-417.	3.8	50
162	Web-based design and evaluation of T-cell vaccine candidates. <i>Bioinformatics</i> , 2008, 24, 1639-1640.	4.1	49

#	ARTICLE	IF	CITATIONS
163	Recapitulation of HIV-1 Env-antibody coevolution in macaques leading to neutralization breadth. <i>Science</i> , 2021, 371, .	12.6	49
164	The KIR and CD94/NKG2 families of molecules in the rhesus monkey. <i>Immunological Reviews</i> , 2001, 183, 25-40.	6.0	47
165	jpHMM at GOBICS: a web server to detect genomic recombinations in HIV-1. <i>Nucleic Acids Research</i> , 2006, 34, W463-W465.	14.5	47
166	Construction and Evaluation of Novel Rhesus Monkey Adenovirus Vaccine Vectors. <i>Journal of Virology</i> , 2015, 89, 1512-1522.	3.4	47
167	Breadth of cellular and humoral immune responses elicited in rhesus monkeys by multi-valent mosaic and consensus immunogens. <i>Virology</i> , 2012, 428, 121-127.	2.4	46
168	Polyvalent vaccine approaches to combat HIV-1 diversity. <i>Immunological Reviews</i> , 2017, 275, 230-244.	6.0	46
169	HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Antibody Responses and Durability among Vaccinees. <i>Journal of Virology</i> , 2018, 92, .	3.4	46
170	Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial. <i>Nature Medicine</i> , 2022, 28, 1288-1296.	30.7	44
171	The TRIM5 Gene Modulates Penile Mucosal Acquisition of Simian Immunodeficiency Virus in Rhesus Monkeys. <i>Journal of Virology</i> , 2011, 85, 10389-10398.	3.4	43
172	Full-Length HIV-1 Immunogens Induce Greater Magnitude and Comparable Breadth of T Lymphocyte Responses to Conserved HIV-1 Regions Compared with Conserved-Region-Only HIV-1 Immunogens in Rhesus Monkeys. <i>Journal of Virology</i> , 2012, 86, 11434-11440.	3.4	42
173	A Multivalent Clade C HIV-1 Env Trimer Cocktail Elicits a Higher Magnitude of Neutralizing Antibodies than Any Individual Component. <i>Journal of Virology</i> , 2015, 89, 2507-2519.	3.4	42
174	Vaccine-Induced Linear Epitope-Specific Antibodies to Simian Immunodeficiency Virus SIVmac239 Envelope Are Distinct from Those Induced to the Human Immunodeficiency Virus Type 1 Envelope in Nonhuman Primates. <i>Journal of Virology</i> , 2015, 89, 8643-8650.	3.4	42
175	A multiple-alignment based primer design algorithm for genetically highly variable DNA targets. <i>BMC Bioinformatics</i> , 2013, 14, 255.	2.6	41
176	Maternal viral load and rate of disease progression among vertically HIV-1-infected children. <i>Aids</i> , 2004, 18, 99-108.	2.2	40
177	Genetic Characterization of Diverse HIV-1 Strains in an Immigrant Population Living in New York City. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006, 41, 399-404.	2.1	40
178	Comparison of Immunogenicity in Rhesus Macaques of Transmitted-Founder, HIV-1 Group M Consensus, and Trivalent Mosaic Envelope Vaccines Formulated as a DNA Prime, NYVAC, and Envelope Protein Boost. <i>Journal of Virology</i> , 2015, 89, 6462-6480.	3.4	40
179	T cell-based strategies for HIV-1 vaccines. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 713-722.	3.3	39
180	Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial. <i>Nature Medicine</i> , 2021, 27, 1718-1724.	30.7	39

#	ARTICLE	IF	CITATIONS
181	HIV-1 Inpatient Sequence Diversity in the Immunogenic V3 Region. <i>AIDS Research and Human Retroviruses</i> , 1992, 8, 1461-1465.	1.1	38
182	Analysis of HIV-1 subtype B third variable region peptide motifs for induction of neutralizing antibodies against HIV-1 primary isolates. <i>Virology</i> , 2006, 345, 44-55.	2.4	37
183	Quantification of the epitope diversity of HIV-1-specific binding antibodies by peptide microarrays for global HIV-1 vaccine development. <i>Journal of Immunological Methods</i> , 2015, 416, 105-123.	1.4	37
184	Epigraph: A Vaccine Design Tool Applied to an HIV Therapeutic Vaccine and a Pan-Filovirus Vaccine. <i>Scientific Reports</i> , 2016, 6, 33987.	3.3	35
185	Increased Valency of Conserved-mosaic Vaccines Enhances the Breadth and Depth of Epitope Recognition. <i>Molecular Therapy</i> , 2016, 24, 375-384.	8.2	35
186	First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector. <i>Journal of Infectious Diseases</i> , 2018, 218, 633-644.	4.0	35
187	Difficult-to-neutralize global HIV-1 isolates are neutralized by antibodies targeting open envelope conformations. <i>Nature Communications</i> , 2019, 10, 2898.	12.8	35
188	Partial Protection of Simian Immunodeficiency Virus (SIV)-Infected Rhesus Monkeys against Superinfection with a Heterologous SIV Isolate. <i>Journal of Virology</i> , 2009, 83, 2686-2696.	3.4	34
189	Cross-Reactive CD8+ T Cell Epitopes Identified in US Adolescent Minorities. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2003, 33, 426-438.	2.1	33
190	Killer cell immunoglobulin-like receptors (KIR) of the African origin <i>Macaca mulatta</i> monkey: evidence for recombination events in the evolution of KIR. <i>European Journal of Immunology</i> , 2005, 35, 922-935.	2.9	32
191	Increased Sequence Diversity Coverage Improves Detection of HIV-Specific T Cell Responses. <i>Journal of Immunology</i> , 2007, 179, 6638-6650.	0.8	32
192	Epitope-Specific CD8 ⁺ T Lymphocytes Cross-Recognize Mutant Simian Immunodeficiency Virus (SIV) Sequences but Fail To Contain Very Early Evolution and Eventual Fixation of Epitope Escape Mutations during SIV Infection. <i>Journal of Virology</i> , 2011, 85, 3746-3757.	3.4	32
193	Identification of a Novel Clade of Human Immunodeficiency Virus Type 1 in Democratic Republic of Congo. <i>AIDS Research and Human Retroviruses</i> , 2002, 18, 817-823.	1.1	30
194	Coping with Viral Diversity in HIV Vaccine Design: A Response to Nickle et al.. <i>PLoS Computational Biology</i> , 2008, 4, e15.	3.2	30
195	Autologous Neutralizing Antibodies to the Transmitted/Founder Viruses Emerge Late after Simian Immunodeficiency Virus SIVmac251 Infection of Rhesus Monkeys. <i>Journal of Virology</i> , 2010, 84, 6018-6032.	3.4	30
196	Distinct Evolutionary Pressures Underlie Diversity in Simian Immunodeficiency Virus and Human Immunodeficiency Virus Lineages. <i>Journal of Virology</i> , 2012, 86, 13217-13231.	3.4	30
197	Characterization and Immunogenicity of a Novel Mosaic M HIV-1 gp140 Trimer. <i>Journal of Virology</i> , 2014, 88, 9538-9552.	3.4	30
198	Increased detection of HIV-specific T cell responses by combination of central sequences with comparable immunogenicity. <i>Aids</i> , 2008, 22, 447-456.	2.2	29

#	ARTICLE	IF	CITATIONS
199	Exploring the Role of Glycans in the Interaction of SARS-CoV-2 RBD and Human Receptor ACE2. <i>Viruses</i> , 2021, 13, 927.	3.3	29
200	Cross-reactive monoclonal antibodies to multiple HIV-1 subtype and SIVcpz envelope glycoproteins. <i>Virology</i> , 2009, 394, 91-98.	2.4	28
201	Associations between Amino Acids in the Evolution of HIV Type 1 Protease Sequences under Indinavir Therapy. <i>AIDS Research and Human Retroviruses</i> , 1999, 15, 247-253.	1.1	27
202	Centralized HIV-1 Envelope Immunogens and Neutralizing Antibodies. <i>Current HIV Research</i> , 2007, 5, 572-577.	0.5	27
203	Genotype 1 and global hepatitis C T-cell vaccines designed to optimize coverage of genetic diversity. <i>Journal of General Virology</i> , 2010, 91, 1194-1206.	2.9	27
204	Recombination-mediated escape from primary CD8+ T cells in acute HIV-1 infection. <i>Retrovirology</i> , 2014, 11, 69.	2.0	27
205	Longitudinal Antigenic Sequences and Sites from Intra-Host Evolution (LASSIE) Identifies Immune-Selected HIV Variants. <i>Viruses</i> , 2015, 7, 5443-5475.	3.3	26
206	HIV Sequence Signatures and Similarities. , 2002, , 55-72.		25
207	Epitopes Immediately below the Base of the V3 Loop of gp120 as Targets for the Initial Autologous Neutralizing Antibody Response in Two HIV-1 Subtype B-Infected Individuals. <i>Journal of Virology</i> , 2011, 85, 9286-9299.	3.4	24
208	A Multi-Component Prime-Boost Vaccination Regimen with a Consensus MOMP Antigen Enhances <i>Chlamydia trachomatis</i> Clearance. <i>Frontiers in Immunology</i> , 2016, 7, 162.	4.8	24
209	Histidine 375 Modulates CD4 Binding in HIV-1 CRF01_AE Envelope Glycoproteins. <i>Journal of Virology</i> , 2017, 91, .	3.4	23
210	Panels of HIV-1 Subtype C Env Reference Strains for Standardized Neutralization Assessments. <i>Journal of Virology</i> , 2017, 91, .	3.4	23
211	mRNA-encoded HIV-1 Env trimer ferritin nanoparticles induce monoclonal antibodies that neutralize heterologous HIV-1 isolates in mice. <i>Cell Reports</i> , 2022, 38, 110514.	6.4	23
212	HIV Type 1 V3 Region Primer-Induced Antibody Suppression Is Overcome by Administration of C4-V3 Peptides as a Polyvalent Immunogen. <i>AIDS Research and Human Retroviruses</i> , 1995, 11, 211-221.	1.1	22
213	Hitting the sweet spot: exploiting HIV-1 glycan shield for induction of broadly neutralizing antibodies. <i>Current Opinion in HIV and AIDS</i> , 2020, 15, 267-274.	3.8	22
214	The Sequential Introduction of HIV-1 Subtype B and CRF01AE in Singapore by Sexual Transmission: Accelerated V3 Region Evolution in a Subpopulation of Asian CRF01 Viruses. <i>Virology</i> , 2002, 304, 311-329.	2.4	21
215	Characterization of the SARS-CoV-2 B.1.621 (Mu) variant. <i>Science Translational Medicine</i> , 2022, 14, eabm4908.	12.4	21
216	The evolutionary rate dynamically tracks changes in HIV-1 epidemics: Application of a simple method for optimizing the evolutionary rate in phylogenetic trees with longitudinal data. <i>Epidemics</i> , 2009, 1, 230-239.	3.0	20

#	ARTICLE	IF	CITATIONS
217	Designing and Testing Broadly-Protective Filoviral Vaccines Optimized for Cytotoxic T-Lymphocyte Epitope Coverage. PLoS ONE, 2012, 7, e44769.	2.5	20
218	Complete protection of the BALB/c and C57BL/6J mice against Ebola and Marburg virus lethal challenges by pan-filovirus T-cell epitope vaccine. PLoS Pathogens, 2019, 15, e1007564.	4.7	20
219	A computational framework for the analysis of peptide microarray antibody binding data with application to HIV vaccine profiling. Journal of Immunological Methods, 2013, 395, 1-13.	1.4	19
220	Hepatitis C Genotype 1 Mosaic Vaccines Are Immunogenic in Mice and Induce Stronger T-Cell Responses than Natural Strains. Vaccine Journal, 2013, 20, 302-305.	3.1	19
221	HIV Type 1 Molecular Clones Able to Use the Bonzo/STRL-33 Coreceptor for Virus Entry. AIDS Research and Human Retroviruses, 2001, 17, 217-227.	1.1	18
222	Structure and Function of CC-Chemokine Receptor 5 Homologues Derived from Representative Primate Species and Subspecies of the Taxonomic Suborders Prosimii and Anthropoidea. Journal of Virology, 2003, 77, 12310-12318.	3.4	18
223	T Cell Responses in HIV Type 1-Infected Adolescent Minorities Share Similar Epitope Specificities with Whites Despite Significant Differences in HLA Class I Alleles. AIDS Research and Human Retroviruses, 2003, 19, 1017-1026.	1.1	18
224	HIV-1 intra-subtype superinfection rates: estimates using a structured coalescent with recombination. Infection, Genetics and Evolution, 2005, 5, 85-95.	2.3	18
225	Identification of amino acid substitutions associated with neutralization phenotype in the human immunodeficiency virus type-1 subtype C gp120. Virology, 2011, 409, 163-174.	2.4	18
226	Genital Tract Sequestration of SIV following Acute Infection. PLoS Pathogens, 2011, 7, e1001293.	4.7	18
227	Alternative Effector-Function Profiling Identifies Broad HIV-Specific T-Cell Responses in Highly HIV-Exposed Individuals Who Remain Uninfected. Journal of Infectious Diseases, 2015, 211, 936-946.	4.0	18
228	Antigenicity-defined conformations of an extremely neutralization-resistant HIV-1 envelope spike. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 4477-4482.	7.1	18
229	HIV-1 Consensus Envelope-Induced Broadly Binding Antibodies. AIDS Research and Human Retroviruses, 2017, 33, 859-868.	1.1	18
230	Graph-based optimization of epitope coverage for vaccine antigen design. Statistics in Medicine, 2018, 37, 181-194.	1.6	18
231	Converging on an HIV Vaccine. Science, 2011, 333, 1589-1590.	12.6	17
232	Effect of Glycosylation on an Immunodominant Region in the V1V2 Variable Domain of the HIV-1 Envelope gp120 Protein. PLoS Computational Biology, 2016, 12, e1005094.	3.2	17
233	Effective Cytotoxic T Lymphocyte Targeting of Persistent HIV-1 during Antiretroviral Therapy Requires Priming of Naive CD8 + T Cells. MBio, 2016, 7, .	4.1	16
234	A single, continuous metric to define tiered serum neutralization potency against HIV. ELife, 2018, 7, .	6.0	16

#	ARTICLE	IF	CITATIONS
235	Molecular Characterization of a Highly Divergent HIV Type 1 Isolate Obtained Early in the AIDS Epidemic from the Democratic Republic of Congo. <i>AIDS Research and Human Retroviruses</i> , 2001, 17, 1217-1222.	1.1	14
236	Epigraph hemagglutinin vaccine induces broad cross-reactive immunity against swine H3 influenza virus. <i>Nature Communications</i> , 2021, 12, 1203.	12.8	14
237	Engineering well-expressed, V2-immunofocusing HIV-1 envelope glycoprotein membrane trimers for use in heterologous prime-boost vaccine regimens. <i>PLoS Pathogens</i> , 2021, 17, e1009807.	4.7	13
238	Tetravalent Immunogen Assembled from Conserved Regions of HIV-1 and Delivered as mRNA Demonstrates Potent Preclinical T-Cell Immunogenicity and Breadth. <i>Vaccines</i> , 2020, 8, 360.	4.4	12
239	HIV-1 Reverse Transcriptase: A Diversity Generator and Quasispecies Regulator. <i>Annals of the New York Academy of Sciences</i> , 1993, 693, 65-70.	3.8	11
240	Quantification of the Resilience and Vulnerability of HIV-1 Native Glycan Shield at Atomistic Detail. <i>IScience</i> , 2020, 23, 101836.	4.1	11
241	Search for the Origin of HIV and AIDS. <i>Science</i> , 2000, 289, 1140-1141.	12.6	10
242	Rare HLA Drive Additional HIV Evolution Compared to More Frequent Alleles. <i>AIDS Research and Human Retroviruses</i> , 2009, 25, 297-303.	1.1	10
243	Envelope Vaccination Shapes Viral Envelope Evolution following Simian Immunodeficiency Virus Infection in Rhesus Monkeys. <i>Journal of Virology</i> , 2010, 84, 953-963.	3.4	10
244	Immunogenicity of NYVAC Prime-Protein Boost Human Immunodeficiency Virus Type 1 Envelope Vaccination and Simian-Human Immunodeficiency Virus Challenge of Nonhuman Primates. <i>Journal of Virology</i> , 2018, 92, .	3.4	10
245	Dendritic cells focus CTL responses toward highly conserved and topologically important HIV-1 epitopes. <i>EBioMedicine</i> , 2021, 63, 103175.	6.1	10
246	Mother-to-Child Transmission in the United States of Subtypes D and A/G Human Immunodeficiency Virus Type 1. <i>AIDS Research and Human Retroviruses</i> , 2002, 18, 413-417.	1.1	9
247	HIV classification using the coalescent theory. <i>Bioinformatics</i> , 2010, 26, 1409-1415.	4.1	9
248	Modeling sequence evolution in HIV-1 infection with recombination. <i>Journal of Theoretical Biology</i> , 2013, 329, 82-93.	1.7	9
249	Effect of epitope variant co-delivery on the depth of CD8 T cell responses induced by HIV-1 conserved mosaic vaccines. <i>Molecular Therapy - Methods and Clinical Development</i> , 2021, 21, 741-753.	4.1	9
250	Evaluation of Different V3 Peptides in an Enzyme Immunoassay for Specific HIV Type 1 Group O Antibody Detection. <i>AIDS Research and Human Retroviruses</i> , 1998, 14, 963-972.	1.1	6
251	Vaccine-Induced CD8+ T Lymphocytes of Rhesus Monkeys Recognize Variant Forms of an HIV Epitope but Do Not Mediate Optimal Functional Activity. <i>Journal of Immunology</i> , 2011, 186, 5663-5674.	0.8	6
252	Estimating the Timing of Early Simian-Human Immunodeficiency Virus Infections: a Comparison between Poisson Fitter and BEAST. <i>MBio</i> , 2020, 11, .	4.1	6

#	ARTICLE	IF	CITATIONS
253	Preexisting memory CD4+ T cells contribute to the primary response in an HIV-1 vaccine trial. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	6
254	Recent Evolutionary History of Human Immunodeficiency Virus Type 1 Subtype B&E”Response. <i>Journal of Molecular Evolution</i> , 2003, 56, 643-644.	1.8	5
255	Expression and evolutionary analysis of West Nile virus (Merion Strain). <i>Journal of NeuroVirology</i> , 2005, 11, 544-556.	2.1	5
256	Epidemiological and Immunological Implications of the Global Variability of HIV-1. , 0, , 1-32.		5
257	Comment to the Letter to the Editor. <i>AIDS Research and Human Retroviruses</i> , 1998, 14, 923-924.	1.1	4
258	Capturing viral diversity for in-vitro test reagents and HIV vaccine immunogen design. <i>Current Opinion in HIV and AIDS</i> , 2007, 2, 183-188.	3.8	4
259	Cross-reactive potential of human T-lymphocyte responses in HIV-1 infection. <i>Vaccine</i> , 2014, 32, 3995-4000.	3.8	4
260	Quantification of the Resilience and Vulnerability of HIV-1 Native Glycan Shield at Atomistic Detail. <i>SSRN Electronic Journal</i> , 0, , .	0.4	4
261	A Plea for Justice for Jailed Medical Workers. <i>Science</i> , 2006, 314, 924-925.	12.6	3
262	jpHMM: improving the reliability of recombination prediction in HIV-1. <i>Nucleic Acids Research</i> , 2010, 38, 1059-1059.	14.5	3
263	Building on the past to define an efficient path to an HIV vaccine. <i>Expert Review of Vaccines</i> , 2011, 10, 929-931.	4.4	3
264	Integrated sequence and immunology filovirus database at Los Alamos. <i>Database: the Journal of Biological Databases and Curation</i> , 2016, 2016, baw047.	3.0	3
265	Cryptic Multiple HIV-1 Infection Revealed by Early, Frequent, and Deep Sampling during Acute Infection. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A58-A58.	1.1	2
266	Structural and genetic convergence of HIV-1 neutralizing antibodies in vaccinated non-human primates. <i>PLoS Pathogens</i> , 2021, 17, e1009624.	4.7	2
267	Network Analysis of the Communication Pathways in HIV-1 Envelope Proteins For Mechanistic Understanding of Immune Escape. <i>Biophysical Journal</i> , 2011, 100, 227a-228a.	0.5	0
268	AIDS Research Pioneer Gerry Myers Dies. <i>AIDS Research and Human Retroviruses</i> , 2011, 27, 453-454.	1.1	0
269	HLA and HIV Infection Progression: Application of the Minimum Description Length Principle to Statistical Genetics. <i>Lecture Notes in Computer Science</i> , 2006, , 1-12.	1.3	0
270	Research on infectious disease dynamics. Introduction. <i>Epidemics</i> , 2009, 1, 1.	3.0	0